Pemetrexed disodium in ovarian cancer treatment

Bibliography

• Jemal A, Siegel R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-8
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183-203
   PubMed Web of Science ®Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, Carcinoma of the ovary. FIGO 6th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95:161-92
   PubMed Web of Science ®Google Scholar
• Colombo N, Peiretti M, Parma G, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:23-30
   PubMed Web of Science ®Google Scholar
• Harter P, Hilpert F, Mahner S, Role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev Anticancer Ther 2009;9:917-22
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16
   PubMed Web of Science ®Google Scholar
• Wagner C. Biochemical role of folate in cellular metabolism. Folate in Health and Disease; Marcel Dekker New York: 1995
   Google Scholar
• Parmar MKLJ, Colombo N, du Bois A, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-18
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D, Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26:890-6
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9
   PubMed Web of Science ®Google Scholar
• Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl 1):3-11
   PubMed Web of Science ®Google Scholar
• Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007;64:129-38
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412
   PubMed Web of Science ®Google Scholar
• Abushahin F, Singh DK, Lurain JR, Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7
   PubMed Web of Science ®Google Scholar
• Vandenput I, Amant F, Neven P, Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:83-7
   PubMed Web of Science ®Google Scholar
• Gordon AN, Granai CO, Rose PG, Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18:3093-100
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22
   PubMed Web of Science ®Google Scholar
• Naumann RW, Symanowski JT, Ghamande SA, PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum resistant ovarian cancer. J Clin Oncol 2010;28: LBA5012b
   PubMed Web of Science ®Google Scholar
• Bailey LB, Gregory JF III. Folate metabolism and requirements. J Nutr 1999;129:779-82
   PubMed Web of Science ®Google Scholar
• Rustum YM, Harstrick A, Cao S, Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997;15:389-400
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK, Mercer RD, Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 1948;238:787-93
   PubMed Web of Science ®Google Scholar
• Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010;2:293-301
   PubMedGoogle Scholar
• Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005;27:1343-82
   PubMed Web of Science ®Google Scholar
• Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009;11:e4
   PubMed Web of Science ®Google Scholar
• Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43
   PubMed Web of Science ®Google Scholar
• Qiu A, Jansen M, Sakaris A, Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28
   PubMed Web of Science ®Google Scholar
• Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52
   PubMed Web of Science ®Google Scholar
• Shih C, Chen VJ, Gossett LS, LY231514, a pyrrolo[2,3-d]pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23
   PubMed Web of Science ®Google Scholar
• Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29(Suppl 18):3-17
   PubMed Web of Science ®Google Scholar
• Pizzorno G, Moroson BA, Cashmore AR, Multifactorial resistance to 5,10 dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995;55:566-73
   PubMed Web of Science ®Google Scholar
• Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 1999;44:427-32
   PubMed Web of Science ®Google Scholar
• de Jonge MJ, Punt CJ, Sparreboom A, Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002;20:1923-31
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Burris HA, Dorr FA, Initial phase I evaluation of the novel thymidylate synthase inhibitor LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-50
   PubMed Web of Science ®Google Scholar
• McDonald AC, Vasey PA, Adams L. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-10
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Kuhn JG, Burris HA, A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80
   PubMed Web of Science ®Google Scholar
• Latz JE, Chaudhary A, Ghosh A, Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006;57:401-11
   PubMed Web of Science ®Google Scholar
• Sørensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011;7:919-28
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Co. ALIMTA (pemetrexcd disodium) injection, powder, lyophillized. for solution Tor intravenous use: US prescribing information [online]. Available from: http://pi. lilly.com/us/alimta-pi.pdf [Accessed 20 July 2009]
   Google Scholar
• Dickgreber NJ, Diaz Padilla I, Paz-Ares LG, Th. safety and pharmacokinetics (PK.) of pemetrexed (PEM) in patients with third-space fluid (TSF). J Clin Oncol 2008;26:2555
   Google Scholar
• Hughes A, Calvert P, Azzabi A, Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-44
   PubMed Web of Science ®Google Scholar
• Dickgreber NJ, Fink TH, Latz JE, Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 2009;15:382-9
   PubMed Web of Science ®Google Scholar
• Hanauske A, Chen V, Paoletti P, Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-73
   PubMed Web of Science ®Google Scholar
• Hammond L, Villalona-Calero M, Eckhardt G, A Phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA) LY231514 with folic acid. Proc Am Soc Clin Oncol 1998;17:225
   Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz DE, Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
   PubMed Web of Science ®Google Scholar
• Rinaldi DA. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 1999;26:82-8
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Center for Drug Evaluation and Research. Alimta. Available from: http:/www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s018s021s022lbl.pdf [Last accessed November 2009]
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics. Alimta. Available from: http://www.emea.europa. eu/humandocs/Humans/EPAR/alimta/alimta.htm [Last accessed November 2009]
   Google Scholar
• Gridelli C, Maione P, Rossi A, Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf 2011;10:311-17
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Brodowicz T, Shepherd FA, Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70
   PubMed Web of Science ®Google Scholar
• Toffoli G, Russo A, Gallo A, Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998;79:121-6
   PubMed Web of Science ®Google Scholar
• Corona G, Giannini F, Fabris M, Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 1998;75:125-33
   PubMed Web of Science ®Google Scholar
• Markert S, Lassmann S, Gabriel B, Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res 2008;28:3567-72
   PubMed Web of Science ®Google Scholar
• Crane LM, Arts HJ, van Oosten M, The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108:619-26
   PubMed Web of Science ®Google Scholar
• Matherly L, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-28
   PubMed Web of Science ®Google Scholar
• Miotti S, Bagnoli M, Ottone F, Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997;65:479-91
   PubMed Web of Science ®Google Scholar
• Hensley ML, Larkin J, Fury M, A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res 2008;14:6310-16
   PubMed Web of Science ®Google Scholar
• Sehouli J, Camara O, Mahner S, A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer Chemother Pharmacol 2010;66:861-8
   PubMed Web of Science ®Google Scholar
• Richards DA, Loesch D, Vukelja SJ, Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. Invest New Drugs 2011;29:963-70
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Horowitz NS, Campos SM, Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008;26:5761-6
   PubMed Web of Science ®Google Scholar
• Vergote I, Calvert H, Kania M, A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;45:1415-23
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Krasner CN, Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:2686-91
   PubMed Web of Science ®Google Scholar
• Gasent-Blesa JM, Alberola Candel V, Provencio Pulla M, Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol 2009;11:35-40
   PubMed Web of Science ®Google Scholar
• Mey V, Giovannetti E, De Braud F, In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006;95:289-97
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Danesi R, Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004;10:2936-43
   PubMed Web of Science ®Google Scholar
• Sehouli J, Alvarez AM, Manouchehrpour S, A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 2010;16:1710-18
   PubMed Web of Science ®Google Scholar
• Adjei AA, Mandrekar SJ, Dy GK, Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-19
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Gooding WE, Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140-5
   PubMed Web of Science ®Google Scholar
• Vella N, Aiello M, Russo AE, ‘Genetic profiling’ and ovarian cancer therapy (Review). Mol Med Rep 2011;4:771-7
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Okamoto W, Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-601
   PubMed Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
   PubMed Web of Science ®Google Scholar
• Gusella M, Padrini R. G > C SNP of thymidylate synthase with respect to colorectal cancer. Pharmacogenomics 2007;8:985-96
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=pemetrexed+ovarian
   Google Scholar